Confusión respecto a Pembrolizumab (Keytruda), una droga que anuncia un esperado cambio sobre el tratamiento del cáncer.

A landmark cancer drug approved last year seemed to herald a long-anticipated change in the treatment of some tumours: with medicines selected on the basis of molecular markers, rather than the tissue in which the cancer first took root.

Noticia completa